Amgen Inc. (AMGN)

221.10
2.60 1.20
NASDAQ : Health Technology
Prev Close 223.72
Open 223.49
Day Low/High 218.25 / 224.28
52 Wk Low/High 170.56 / 244.99
Volume 3.65M
Avg Volume 3.37M
Exchange NASDAQ
Shares Outstanding 588.25M
Market Cap 133.48B
EPS 13.00
P/E Ratio 17.77
Div & Yield 6.40 (2.66%)
Jim Cramer Previews the Fed Statement and Talks Apple, Oil, Amgen and MSCI

Jim Cramer Previews the Fed Statement and Talks Apple, Oil, Amgen and MSCI

TheStreet's Jim Cramer discusses Wednesday's trending stocks.

Health Care Putting in a Base

Healthcare stocks had a heckuva four-year period of over-performance that ended in the summer of 2015. Since then the Health Care Select Sector SPDR ETF (40% pharma and 15% biotech) has had a series of trading-range moves as sector prices lagged. La...

Egalet Makes Friday's Biotech Mailbag

Egalet Makes Friday's Biotech Mailbag

Why the name is sagging, and what it will take to spur the sector higher.

Cramer: When a Trump Tweet Is a Buy Signal

Cramer: When a Trump Tweet Is a Buy Signal

Drug companies are the latest targets/beneficiaries.

Jim Cramer on Donald Trump's Drug Tweet: "No One Really Knows What He Means"

Jim Cramer on Donald Trump's Drug Tweet: "No One Really Knows What He Means"

Jim Cramer says no one really knows what President Trump means when it comes to drug pricing.

Drugmakers Suffer After Trump Tweet

Drugmakers Suffer After Trump Tweet

Stocks were under pressure again after Donald Trump made vague promises to lower drug prices.

Amgen Is Making an Important Upside Breakout

Amgen Is Making an Important Upside Breakout

The 50-day moving average is crossing the 200-day for a bullish golden cross; go long here.

Amgen Shows a Bullish Breakout

Amgen Shows a Bullish Breakout

There is more upside to come for this stock.

Health Care ETF Has Been Ailing

Health Care ETF Has Been Ailing

You might want to review your holdings in the sector.

Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This

Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This

Some tried-and-true indicators show what's really going on with the market.

Amgen estimates, target increased at BMO

Streamlined FDA Approval Process Would Boost Drug Makers

Streamlined FDA Approval Process Would Boost Drug Makers

Would get drugs to market faster and possibly more cheaply.

Novice Trade: AbbVie

Novice Trade: AbbVie

Getting FDA to streamline its approval process would boost drug makers.

There Is So Little Attention Paid to the Fed Meeting

There Is So Little Attention Paid to the Fed Meeting

The Fed is simply not a market catalyst this time.

Nike, Disney, Amgen: When Charts, Fundamentals Don't Match

Nike, Disney, Amgen: When Charts, Fundamentals Don't Match

There's not much reason to be bullish on these stocks.

3 Stocks Ripe for a Big Rebound in 2017

3 Stocks Ripe for a Big Rebound in 2017

Nike, Disney and Amgen shares struggled in 2016. Here is why they are ready to rebound in 2017.

5 Companies That Will Benefit Most From a $500 Billion Tax Holiday

5 Companies That Will Benefit Most From a $500 Billion Tax Holiday

Apple could be the biggest winner if the Trump administration grants U.S. companies a repatriation tax holiday.

Drug Stocks Find Trump Animus a Bitter Pill

Drug Stocks Find Trump Animus a Bitter Pill

The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

These companies show signs of a change of direction.

5 Stocks Set to Rocket Higher

5 Stocks Set to Rocket Higher

Looks like these five stocks could rocket higher.

Closing Bell: Active Oil Rigs Rise; Dow Gets Close to 20K but Falls Short

Closing Bell: Active Oil Rigs Rise; Dow Gets Close to 20K but Falls Short

The Dow Jones Industrial Average came agonizingly close to its 20,000 milestone before falling short and backing off.

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.

Prepare for Biotech Action Aplenty Today

As we await the jobs report, there is significant news across the biotech sector in the past 24 hours on some names I have mentioned in these pages. Amgen should be up nicely today after a judge stated that Regeneron would have to pull its PCKS9 inh...

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.

Amgen Establishes a Bottom and Signals It's Time to Buy

Amgen Establishes a Bottom and Signals It's Time to Buy

Traders could buy a dip to $150 if available or they can buy strength above $155, which ever comes first.

My Top Pick for 2017: Short QQQ

My Top Pick for 2017: Short QQQ

Six reasons why the Nasdaq 100 ETF seems ready to pull back.

My Top Pick for 2017: Short QQQ

My trade of the year for 2017 is to short the PowerShares QQQ Trust ETF , which tracks the Nasdaq 100 index. Here's my investment thesis for this play: The Nasdaq 100 Already Has Rallied QQQ already has risen from about $96 a share at the market's F...

Amgen Can Handle Patent Expiration Risks

Amgen Can Handle Patent Expiration Risks

It's got several newly launched promising drugs, a number of late-stage prospects and strong financials.

Expect Some Big-Cap Biotech Love in 2017

We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this se...